According to a pooled-analysis of anti-CTLA-4 Ipilimumab, more than 20% of treated patients with unresectable or metastatic melanoma experienced long-term survival for up to 10 years and suggested no cancer recurrence thereafter (Schadendorf et al., 2015). This evidence concerns the gene CTLA4 and metastatic melanoma.